Assessment of Geriatric Evaluations Impact on New AML Guidance

Description

The goal of the study is to measure physiologic age (there is no current formal definition but is meant to imply that patients should be evaluated holistically rather than on age alone) at baseline in newly diagnosed AML patients over 50 years receiving either intensive or non-intensive treatment. This information will be used to evaluate toxicity, early mortality, remission rates and long term survival.

Conditions

AML, Adult

Study Overview

Study Details

Study overview

The goal of the study is to measure physiologic age (there is no current formal definition but is meant to imply that patients should be evaluated holistically rather than on age alone) at baseline in newly diagnosed AML patients over 50 years receiving either intensive or non-intensive treatment. This information will be used to evaluate toxicity, early mortality, remission rates and long term survival.

AGE-ING (Assessment of Geriatric Evaluations Impact on New AML Guidance) Study

Assessment of Geriatric Evaluations Impact on New AML Guidance

Condition
AML, Adult
Intervention / Treatment

-

Contacts and Locations

Philadelphia

Abramson Cancer Center at University of Pennsylvania, Philadelphia, Pennsylvania, United States, 19104

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * AML diagnosis by peripheral flow cytometry and/or bone marrow aspirate and biopsy
  • * New diagnosis being considered for new line of treatment
  • * Age ≥ 50 years.
  • * Performance status 0,1, and 2
  • * Inability to understand or unable to sign a written informed consent
  • * Unable to fill out questionnaires on their own and/or do not have someone to help complete them

Ages Eligible for Study

50 Years to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

Abramson Cancer Center at Penn Medicine,

Catherine Lai, MD, PRINCIPAL_INVESTIGATOR, Abramson Cancer Center at Penn Medicine

Study Record Dates

2025-07-01